Motorola Solutions Boosts Buyback Authorization to $20B; No Change to WAIT Rating

What happened

Motorola Solutions announced a $2 billion increase to its share repurchase program, raising the total authorization since July 2011 to $20 billion with no expiration date, after having approximately $0.6 billion remaining under the prior $18 billion program as of the second quarter of 2026. This move is consistent with the company's history of returning cash to shareholders, which already included $664 million of repurchases and $546 million of dividends in the first nine months of 2025. The increase signals management confidence in free cash flow generation, with the company guiding to approximately $2.75 billion in operating cash flow for 2025. However, it does not alter the fundamental investment case, which remains constrained by a premium valuation at roughly 31x trailing P/E and 29x EV/EBITDA, along with risks from U.K. Airwave litigation and elevated leverage following the Silvus acquisition. At the current price of about $394, the DeepValue model still rates MSI a WAIT, with an attractive entry near $355 and a trim level above $450.

Implication

The larger buyback authorization underscores management's commitment to returning capital and may provide modest support to per-share earnings over time, but it does not address the key risks that keep MSI a WAIT at approximately $394. The company trades at about 31x trailing EPS and 29x EV/EBITDA, leaving limited margin of safety if Airwave litigation or tariff pressures erode margins. While the buyback could help cushion downside, it also consumes cash that could otherwise reduce the elevated net debt position of $4.45 billion (1.71x EBITDA) following the Silvus acquisition. Investors should treat this news as a confirmation of existing capital allocation rather than a fundamental catalyst; the more important triggers remain Q4 earnings, FY2026 guidance, and legal outcomes on Airwave. A more attractive entry point remains near $355, and we would not add above $450.

Thesis delta

The thesis is unchanged. The buyback increase does not alter our WAIT rating or $355–$450 valuation range; it simply reinforces management's existing capital return posture. If anything, it may slightly support EPS but also signals a preference for buybacks over deleveraging, which keeps balance sheet risk in focus.